UroGen Pharma Ltd. (URGN) financials — revenue, cash, debt and margins

UroGen Pharma Ltd. (URGN) financials — revenue, cash, debt and margins — InspectStocks

Key figures

Trailing twelve months where a flow is involved, latest reported balance where it is not.

Valuation

Market cap: $2B
P/E (TTM): —
Price / sales: 10.47
EV / EBITDA: —
Price / book: —

Cash flow

FCF yield: -8.1%
SBC-adjusted FCF yield: -8.9%
SBC impact: —
Stock compensation (TTM): $16.1M

Margins & growth

Profit margin: -51.7%
Operating margin: -35.3%
Quarterly revenue (year on year): 199.2%
Quarterly earnings (year on year): —

Balance sheet

Cash & investments: $109.3M
Debt: $196.1M
Net cash / (debt): -$86.8M

Where the revenue comes from

Jelmyto is 86% of revenue.

By product or service

Year to Dec 31, 2025 · $109.8M

Jelmyto86%
$94M+4.0% vs. a year earlier
Zusduri14%
$15.8M

What it owns and what it owes

Both on one scale, because both are money — the bar that is taller is the one that matters.

Cash and debt

Cash & InvestmentsTotal Debt

Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.

Where the money goes

Cost of RevenueR&D ExpenseSG&A Expense

Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.

The rest of the series

Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.

Total Revenue

$188.73MQ2 2026+34.3%

1Y: +100.27%2Y: +122.01%5Y: +490.83%

Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.

EBITDA

-$66.3MQ2 2026+38.5%

1Y: +46.19%2Y: +16.15%5Y: +36.68%

Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit

-$97.64MQ2 2026+26.7%-51.7% of revenue

1Y: +37.00%2Y: +14.04%5Y: +12.43%

What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit margin

-51.7%Q2 2026+45.4%

How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.

Free Cash Flow

-$159.14MQ2 2026+4.2%

1Y: -28.83%2Y: -85.00%5Y: -69.55%

Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.

Profit per share

-$4.96Q4 2021+2.2%

1Y: +16.22%

The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.

About UroGen Pharma Ltd.

Ticker: URGN
SEC classification: Pharmaceutical Preparations (2834)
Listed on: Nasdaq
Incorporated in: L3
Financial year ends: December 31
Filer size: Non-accelerated filer<br>Smaller reporting company

About this data

Everything above comes from UroGen Pharma Ltd.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.

Not reported by this filer: Shares outstanding, Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Long-term Debt (current), Short-term Borrowings, Borrowings (total), Dividends paid, Amortization of Intangibles, and Share Repurchases. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.